Form: SCHEDULE 13G

Statement of Beneficial Ownership by Certain Investors






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage reported herein is based on 1,166,625 shares of Common Stock outstanding as of September 30, 2026, as reported by bioAffinity Technologies, Inc. in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the Securities and Exchange Commission on November 6, 2026, plus 986 shares of Common Stock issuable upon the exercise of certain warrants held by HRT Financial LP, for a denominator of 1,167,611 shares.


SCHEDULE 13G



 
HRT FINANCIAL LP
 
Signature:Adam Nunes
Name/Title:CEO
Date:11/19/2026